Breast Cancer

Catriona Jamieson, MD, PhD, discusses the role of stress-activated base editors like ADAR1p150 and APOBEC enzymes in cancer progression and highlights innovative approaches to halt these processes and improve therapeutic outcomes.

The Trop-2-tagreting antibody drug conjugate facilitated improved intracranial penetration with favorable tolerability.

Topical, targeted drug delivery increases drug concentrations at the desired site while also reducing toxicity and unwanted adverse effects.

Digoxen is the active ingredient found in the foxglove plant and is commonly used to treat heart failure.

Presence of comorbidities in older patients with breast cancer complicates treatment decisions.

Black and Native American patients were about 2 to 3 times more likely to die of cancer compared with White patients, and women younger than 50 years were affected more than male patients.

Experts presented results that may transform treatment and clinical practice strategies.

Hormonal contraceptives did not increase breast cancer risk in patients with BRCA2 mutations.

Brentuximab vedotin is approved for treatment of adult and pediatric with classical Hodgkin lymphoma in combination with chemotherapy.

Pharmacists play a vital role in cancer prevention and early detection by educating patients on risk factors, counseling on screening guidelines, and promoting adherence to evidence-based recommendations for common cancers, such as breast, cervical, colorectal, lung, prostate, and skin cancer.

Inclusion of AI improved detection and reduced instances of false-positive test results.

Of these chemicals, 414 were found to be commonly used in plastics and consumer goods, such as food packaging and personal care products.

Pharmacy Times attended the 2024 San Antonio Breast Cancer Symposium from December 10 to December 13.

Pharmacists identify appropriate patients for new oral and antibody drug conjugate treatments and provide counseling to help patients navigate the evolving treatment landscape.

Obesity is associated with increased distant recurrence and breast cancer mortality in all types of early-stage breast cancer.

AI-powered analysis of mammography images can identify women at high long-term risk of breast cancer, enabling targeted prevention strategies.

Adding anthracyclines to chemotherapy may improve survival in high-risk breast cancer patients.

Advancements in prevention address cancer risk in high-risk patients and BRCA mutation carriers.

Combining CDK4/6 and PDL-1 inhibitors enhances treatment responses in patients with hormone receptor positive and triple-negative breast cancer.

Novel therapies and personalized treatment plans are improving outcomes for patients with ER-positive breast cancer.

At the 2024 San Antonio Breast Cancer Symposium, experts discussed the development, clinical impact, and challenges of antibody-drug conjugates (ADCs).

Experts highlight the importance of dosing and regimen optimization in breast cancer to improve treatment tolerability, reduce toxicities, and improve quality of life for patients.

The authors suggest that targeted interventions to mitigate financial toxicity should be implemented to better support patients.

When different skin tones are considered in imaging systems, women will receive more equitable screening and care.

Because these cells are present throughout the body, there may also be implications for other cancer types.